Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 761

1.

Temporal and Spatial Effects and Survival Outcomes Associated with Concordance between Tissue and Blood KRAS Alterations in the Pan-Cancer Setting.

Mardinian K, Okamura R, Kato S, Kurzrock R.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32510. [Epub ahead of print]

PMID:
31199507
2.

The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS.

Clin Cancer Res. 2019 Jun 11. pii: clincanres.1881.2018. doi: 10.1158/1078-0432.CCR-18-1881. [Epub ahead of print]

PMID:
31186313
3.

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer.

Adashek JJ, Junior PNA, Galanina N, Kurzrock R.

J Immunother Cancer. 2019 May 22;7(1):130. doi: 10.1186/s40425-019-0618-9.

4.

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.

Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00180. Epub 2019 Jan 22.

5.

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival.

Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00158. Epub 2019 Jan 25.

6.

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R.

Mol Cancer Ther. 2019 Jun;18(6):1149-1157. doi: 10.1158/1535-7163.MCT-18-1244. Epub 2019 Apr 23.

PMID:
31015311
7.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

PMID:
31011206
8.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.

Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R.

Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22.

PMID:
31011205
9.

Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.

Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R.

Cancer Immunol Res. 2019 Jun;7(6):866-873. doi: 10.1158/2326-6066.CIR-18-0716. Epub 2019 Apr 19.

PMID:
31003990
10.

Schnitzler syndrome associated with MYD88 L265P mutation.

Goodman AM, Cohen PR, Li A, Hinds B, Kurzrock R.

JAAD Case Rep. 2019 Apr 1;5(4):312-316. doi: 10.1016/j.jdcr.2019.02.002. eCollection 2019 Apr. No abstract available.

11.

Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.

Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R.

Mol Cancer Ther. 2019 May;18(5):1001-1011. doi: 10.1158/1535-7163.MCT-17-1038. Epub 2019 Mar 29.

PMID:
30926636
12.

Immune Escape of AML Cells after Transplantation.

Goodman AM, Kurzrock R.

N Engl J Med. 2019 Mar 28;380(13):1289. doi: 10.1056/NEJMc1900424. No abstract available.

PMID:
30917272
13.

Waun Ki Hong (1942-2019) John Mendelsohn (1936-2019).

Lippman SM, Kurzrock R.

Cancer Cell. 2019 Feb 11;35(2):157-160. doi: 10.1016/j.ccell.2019.01.014. Epub 2019 Feb 11. No abstract available.

14.

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J.

Lancet Oncol. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8.

PMID:
30857956
15.

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer.

Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, Mohanty P, Dinarello CA, Simard J.

Oncoimmunology. 2018 Dec 12;8(3):1551651. doi: 10.1080/2162402X.2018.1551651. eCollection 2019.

16.

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy.

Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R.

Oncoimmunology. 2018 Dec 24;8(3):1550341. doi: 10.1080/2162402X.2018.1550341. eCollection 2019.

17.

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.

J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.

19.

Novel patterns of response under immunotherapy.

Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C.

Ann Oncol. 2019 Mar 1;30(3):385-396. doi: 10.1093/annonc/mdz003.

PMID:
30657859
20.

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.

Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00183. Epub 2018 Nov 15.

21.

Identification of targets for prostate cancer immunotherapy.

Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C.

Prostate. 2019 Apr;79(5):498-505. doi: 10.1002/pros.23756. Epub 2019 Jan 6.

PMID:
30614027
22.

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S.

Breast. 2019 Apr;44:29-32. doi: 10.1016/j.breast.2018.12.010. Epub 2018 Dec 20.

PMID:
30609392
23.

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.

Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R.

Cancers (Basel). 2018 Dec 21;11(1). pii: E11. doi: 10.3390/cancers11010011.

24.

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.

Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R.

Cancer. 2019 Apr 1;125(7):1185-1199. doi: 10.1002/cncr.31921. Epub 2018 Dec 24.

25.

Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients.

Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R.

Mol Cancer Ther. 2019 Feb;18(2):448-458. doi: 10.1158/1535-7163.MCT-18-0535. Epub 2018 Dec 6.

PMID:
30523049
26.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS.

J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.

27.

ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis.

Baumgartner JM, Kurzrock R.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):772-773. doi: 10.1245/s10434-018-7029-x. Epub 2018 Nov 12. No abstract available.

PMID:
30421042
28.

An avatar for precision cancer therapy.

Kato S, Kurzrock R.

Nat Biotechnol. 2018 Nov 9;36(11):1053-1055. doi: 10.1038/nbt.4293. No abstract available.

29.

Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response.

Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S, Sharabi AB.

Front Oncol. 2018 Oct 17;8:435. doi: 10.3389/fonc.2018.00435. eCollection 2018.

30.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1.

PMID:
30383888
31.

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match.

Subbiah V, Kurzrock R.

Oncologist. 2019 Jan;24(1):1-3. doi: 10.1634/theoncologist.2017-0519. Epub 2018 Oct 23. No abstract available.

32.

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.

Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R.

Clin Cancer Res. 2018 Dec 15;24(24):6248-6256. doi: 10.1158/1078-0432.CCR-18-1128. Epub 2018 Oct 22.

PMID:
30348637
33.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ.

JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10.

PMID:
30347019
34.

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.

Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R.

Cancer Biol Ther. 2018 Oct 19:1-8. doi: 10.1080/15384047.2018.1523849. [Epub ahead of print]

35.

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.

J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

PMID:
30339520
36.

Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).

Galanina N, Kurzrock R.

Cancer Biol Ther. 2019;20(3):247-251. doi: 10.1080/15384047.2018.1523857. Epub 2018 Oct 11.

PMID:
30307363
37.

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology.

Jardim DL, de Melo Gagliato D, Kurzrock R.

Integr Cancer Ther. 2018 Dec;17(4):1012-1015. doi: 10.1177/1534735418801524. Epub 2018 Sep 19. Review.

38.

Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.

Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R.

Ann Oncol. 2018 Nov 1;29(11):2192-2199. doi: 10.1093/annonc/mdy412.

PMID:
30219896
39.

GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers.

Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R.

Cancer. 2018 Oct 15;124(20):4080-4089. doi: 10.1002/cncr.31724. Epub 2018 Sep 11.

PMID:
30204251
40.

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.

Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R.

Cancer Immunol Res. 2018 Oct;6(10):1129-1135. doi: 10.1158/2326-6066.CIR-18-0121. Epub 2018 Sep 7.

PMID:
30194084
41.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.

Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4. Review.

42.

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.

Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00235. Epub 2018 Jul 13.

43.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23.

PMID:
30139837
44.

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors.

Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS.

Oncotarget. 2018 Jun 22;9(48):28842-28848. doi: 10.18632/oncotarget.25571. eCollection 2018 Jun 22.

45.

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.

Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R.

Ann Surg Oncol. 2018 Aug;25(8):2400-2408. doi: 10.1245/s10434-018-6561-z. Epub 2018 Jun 14.

46.

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R.

JAMA Oncol. 2018 Sep 1;4(9):1237-1244. doi: 10.1001/jamaoncol.2018.1701.

47.

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.

Ikeda S, Schwaederle M, Mohindra M, Fontes Jardim DL, Kurzrock R.

J Hematol Oncol. 2018 Jun 4;11(1):76. doi: 10.1186/s13045-018-0610-8.

48.

Reply to J.J. Tao et al.

Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R.

J Clin Oncol. 2018 Aug 10;36(23):2451. doi: 10.1200/JCO.2018.78.6392. Epub 2018 Jun 1. No abstract available.

PMID:
29856693
49.

Cancer research in the United States: A critical review of current status and proposal for alternative models.

Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J.

Cancer. 2018 Jul 15;124(14):2881-2889. doi: 10.1002/cncr.31522. Epub 2018 May 14. No abstract available.

PMID:
29757456
50.

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.

Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D.

Br J Cancer. 2018 May;118(11):1419-1424. doi: 10.1038/s41416-018-0068-z. Epub 2018 Apr 26.

Supplemental Content

Loading ...
Support Center